Recursion Pharmaceuticals(纳斯达克:RXRX)于周五盘前大跌5.87%,引发了市场广泛关注。
公司近期公布的2022年第四季度财报显示,每股亏损0.53美元,远超分析师预期的0.46美元亏损。营收方面,RXRX季度销售额仅为455万美元,大幅低于市场预期的1904万美元。
这一业绩低于预期的情况可能是导致盘前股价大跌的主要原因。不过,目前尚未有其他公开信息可以解释这一跌幅。投资者或需进一步关注公司未来发展,以判断是否存在更深层次的影响因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.